Drugs / LAENNEC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06493799 | Jul 2024 → Mar 2026 overdue | liver disorder | Green Cross Wellbeing | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05528705 | Sep 2022 → Oct 2023 | shoulder impingement syndrome | Green Cross Wellbeing | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAENNEC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05528705 ↗ |
| Known as | Human Placenta Hydrolysate | “LAENNEC (Human Placenta Hydrolysate) IV” NCT06493799 ↗ |
| Route | Intravenous | “Intravenous Injection” NCT06493799 ↗ |